The Medical – Products industry is currently facing significant challenges stemming from macroeconomic factors such as rising tariffs, inflation, and supply chain disruptions, which have contributed to a collective decline of 26.1% in stock performance over the last year. This contrasts with a 12.7% gain in the Zacks Medical sector and a 21.1% increase in the S&P 500. Furthermore, the industry’s profitability is under strain, with the average price-to-earnings (P/E) ratio standing at 16.3X, compared to the S&P 500’s 20.7X.
Despite these pressures, underlying demand is resilient, bolstered by increased procedural volumes and an aging population, with the ambulatory surgical center (ASC) market projected to reach $205 billion by 2030. Companies such as Terumo, QuidelOrtho, Brainsway, and Lumexa Imaging are responding to industry challenges with strategies focused on cost control and innovation, particularly in advanced diagnostic solutions.
Innovation remains a key growth driver, with over 1,500 FDA-cleared AI/ML-enabled devices currently in the market. The projected market for remote patient monitoring devices is expected to surge to $30.9 billion by 2026 and $110.7 billion by 2033, indicating strong demand for enhanced healthcare technologies despite current economic challenges.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
